Skip to content

An Open Label, Prospective, Multicentre, Non-interventional Study of Iodixanol 270 mg I/mL for Use in Subjects Undergoing Computed Tomographic Angiography (CTA) Examinations in Real World Clinical Practice

An Open Label, Prospective, Multicentre, Non-interventional Study of Iodixanol 270 mg I/mL for Use in Subjects Undergoing Computed Tomographic Angiography (CTA) Examinations in Real World Clinical Practice

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-13003844
Enrollment
Unknown
Registered
2013-11-04
Start date
2013-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary, aortic, head and neck, renal and pulmonary arteries relative conditions

Interventions

none:none

Sponsors

Xuanwu Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) The subject is over 18 years old; (2) Subjects are referred to undergo CTA examination of coronary, aortic, head and neck, renal and pulmonary arteries as part of their routine clinical care; (3) The subject has provided a signed and dated informed consent.

Exclusion criteria

Exclusion criteria: (1) Subject has a known allergy to iodinated contrast agent, including but not limited to hives, anaphylactoid or cardiovascular reactions, laryngeal oedema, and bronchospasm; (2) Subject has atrial fibrillation/flutter or any irregular heart rhythm considered to interfere with temporal acquisition of cardiac CT images. (Only applicable for Coronary CTA); (3) Subject has a resting heart rate of >100 bpm and/or a resting diastolic blood pressure of >100 mm Hg, or a resting heart rate of >70 bpm and beta-blocker therapy is contraindicated. (Only applicable for Coronary CTA); (4) Subject has had a prior CABG procedure; (5) Subject has had a prior pacemaker or internal defibrillator lead implantation. (Only applicable for Coronary CTA); (6) Subject has extensive vessel calcifications identified by non-contrast images. (Only applicable for Coronary CTA); (7) Subject is not willing /unable to discontinue metformin or metformin containing products; (8) Subjects with manifest thyrotoxicosis.

Design outcomes

Primary

MeasureTime frame
imaging quality;

Countries

China

Contacts

Public ContactLi kuncheng

Xuanwu Hospital of Capital Medical University

cjr.likuncheng@vip.163.com+86 13911099059

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026